Abstract
The efficacy of current treatment protocols for childhood cancer is mainly based on empirical studies by adding drugs, changing drug dosages and changing drug combinations. In pediatric acute lymphoblastic leukemia (ALL), this approach has resulted into ∼80% 5-year disease-free survival whereas less favorable results have yet been obtained for acute myeloid leukemia (AML), i.e. ∼50%, and other types of tumors, e.g. ∼60% for medulloblastoma. A further optimization of therapy results requires more insights into the molecular biology of tumor cells, including genetic defects and aberrant expression of genes. This knowledge is needed to rationally develop more specific therapies in which relapse-risk and side-effects of therapy are reduced using targeted drugs. Genome-wide analysis of gene expression levels (mRNA) has revealed many new insights into the biology of leukemic cells. In this review we will discuss the recent progress that has been made in the use of microarrays for identifying new markers and targets for treatment of acute leukemia in children.
Keywords: Gene expression profiling, microarray, classification, drug resistance, outcome, targeted therapy, childhood, acute leukemia
Current Drug Targets
Title: Microarray-Based Identification of New Targets for Specific Therapies in Pediatric Leukemia
Volume: 8 Issue: 6
Author(s): Monique L. den Boer and Rob Pieters
Affiliation:
Keywords: Gene expression profiling, microarray, classification, drug resistance, outcome, targeted therapy, childhood, acute leukemia
Abstract: The efficacy of current treatment protocols for childhood cancer is mainly based on empirical studies by adding drugs, changing drug dosages and changing drug combinations. In pediatric acute lymphoblastic leukemia (ALL), this approach has resulted into ∼80% 5-year disease-free survival whereas less favorable results have yet been obtained for acute myeloid leukemia (AML), i.e. ∼50%, and other types of tumors, e.g. ∼60% for medulloblastoma. A further optimization of therapy results requires more insights into the molecular biology of tumor cells, including genetic defects and aberrant expression of genes. This knowledge is needed to rationally develop more specific therapies in which relapse-risk and side-effects of therapy are reduced using targeted drugs. Genome-wide analysis of gene expression levels (mRNA) has revealed many new insights into the biology of leukemic cells. In this review we will discuss the recent progress that has been made in the use of microarrays for identifying new markers and targets for treatment of acute leukemia in children.
Export Options
About this article
Cite this article as:
den Boer L. Monique and Pieters Rob, Microarray-Based Identification of New Targets for Specific Therapies in Pediatric Leukemia, Current Drug Targets 2007; 8 (6) . https://dx.doi.org/10.2174/138945007780830755
DOI https://dx.doi.org/10.2174/138945007780830755 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design and Development of Anti-Hepatitis B Virus Agents
Current Medicinal Chemistry The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry N-acetylcysteine Versus Placebo for Treating Nail Biting, a Double Blind Randomized Placebo Controlled Clinical Trial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Topical Delivery of Antioxidants
Current Drug Delivery Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews Serum Interleukin-33 as a Biomarker in Predicting Neonatal Sepsis in Premature Infants
Combinatorial Chemistry & High Throughput Screening Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia
Current Neuropharmacology Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Genetic Variation and Atherosclerosis
Current Genomics The Potential of Trace Amines and Their Receptors for Treating Neurological and Psychiatric Diseases
Reviews on Recent Clinical Trials The Male Peripubertal Phase as a Developmental Window for Reproductive Toxicology Studies
Current Pharmaceutical Design Emergence of Azole Therapy for Cancer Associated Fungal Infections and Their Potential Human Toxicity
The Natural Products Journal Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Functions of the Third Intracellular Loop of the Human Melanocortin-3 Receptor
Current Pharmaceutical Design Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Novel Biological Therapies in Severe Asthma: Targeting the Right Trait
Current Medicinal Chemistry Patent Selections
Recent Patents on Regenerative Medicine